NorthWest Biotherapeutics Inc (NWBO)

[TZOR]

Pyr I was just rereading your article from last year again and thought to myself how close you are to reality on a particular point of your article.

Given the choice to subsidize one or the other (insurance carriers will not bear the burden of subsidizing two novel therapies for the same indication), insurers and doctors would certainly choose DCVax-L over Rindo. Also, should data indeed show such an improvement over SOC, the Ph III DCVax-L trial would be halted mid-2015, and a BLA filed. CLDX has to wait until at least early 2017 to learn Rindo's fate. DCVax-L would have been approved long before CLDX receives top-line data on its Ph III trial (let alone begin the process of filing for approval, a process that can take upwards of a year)

Would early August constitute a mid-year halt?

How eerily accurate with CLDX prediction of 2017 as their AA was just postponed by the FDA for their small size and OS primary target?

I chose to remember this PYR and not the new one who appears to influenced without full disclosure.

Also my questions are rhetorical. NWBO is temporarily halted in mid 2015 and CLDX will not see their trial finalized and reviewed anytime soon, 2017 may be accurate.